Investment
Features
FeesSafety
Academy
More
Pluang+

Compare F.N.B. Corporation Common Stock (FNB) vs Humana Inc (HUM) Price & Performance

F.N.B. Corporation Common StockTrade
Humana IncTrade

Price performance (Past 24H)

Key statistics

F.N.B. Corporation Common Stock vs Humana Inc — how do they compare? F.N.B. Corporation Common Stock trades at $16.91 (market cap $6.07B), while Humana Inc trades at $427.33 (market cap $50.48B). The key difference: Humana Inc is far larger — about 8.3× F.N.B. Corporation Common Stock's market cap, and F.N.B. Corporation Common Stock pays the higher dividend (3.05%). Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Humana Inc for 51 Days on average.

FNBHUM
Market Cap
$6.07B$50.48B
Volume
5,600,6091,889,709
Sector
FinancialsHealth
52-Week High
$19.49$433.50
52-Week Low
$14.65$163.67
Typical Hold Time
0 Days51 Days
Enterprise Value
$10.61B$57.83B
Dividend Yield
3.05%0.84%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

F.N.B. Corporation Common Stock

FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.

The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.

Humana Inc

Humana (HUM) trades at $427.59, down 1.36% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is robust, reaching $129.66 billion in 2025, though net income margins have compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and strong institutional buying interest, while the company prepares for Q3 earnings on November 6.

The stock offers upside to the $469.89 consensus target but faces risks from margin pressure and regulatory scrutiny. Earnings beats in recent quarters support momentum, yet profitability trends and Medicare Advantage plan changes require monitoring for sustained growth.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FNB
100% Buy0% Sell
Avg holding period · 0 Days
HUM

No sentiment data available yet.

Top news

Latest headlines on both assets

About F.N.B. Corporation Common Stock

F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.

Read more on FNB →

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM →